LUCERNE
E822410
LUCERNE is a large phase III clinical trial evaluating the efficacy and safety of faricimab for the treatment of neovascular (wet) age-related macular degeneration.
All labels observed (1)
| Label | Occurrences |
|---|---|
| LUCERNE canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T9807335 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
Target entity: LUCERNE Context triple: [faricimab, clinicalTrial, LUCERNE]
-
A.
City of Lucerne
The City of Lucerne is a historic Swiss city and member of the Old Swiss Confederacy, known for its strategic location by Lake Lucerne and its role in late medieval conflicts such as the Burgundian Wars.
-
B.
Cervini
Cervini is the Italian noble family from which Pope Marcellus II (Marcello Cervini) originated.
-
C.
Fürth
Fürth is a historic city in northern Bavaria, Germany, known for its well-preserved old town and proximity to Nuremberg within the Franconian metropolitan region.
-
D.
Murten
Murten is a historic bilingual town in the canton of Fribourg, Switzerland, known for its well-preserved medieval old town and lakeside setting on Lake Murten.
-
E.
Lambermont
Lambermont is the official residence of the Prime Minister of Belgium, located in Brussels.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Target entity: LUCERNE Target entity description: LUCERNE is a large phase III clinical trial evaluating the efficacy and safety of faricimab for the treatment of neovascular (wet) age-related macular degeneration.
-
A.
City of Lucerne
The City of Lucerne is a historic Swiss city and member of the Old Swiss Confederacy, known for its strategic location by Lake Lucerne and its role in late medieval conflicts such as the Burgundian Wars.
-
B.
Cervini
Cervini is the Italian noble family from which Pope Marcellus II (Marcello Cervini) originated.
-
C.
Fürth
Fürth is a historic city in northern Bavaria, Germany, known for its well-preserved old town and proximity to Nuremberg within the Franconian metropolitan region.
-
D.
Murten
Murten is a historic bilingual town in the canton of Fribourg, Switzerland, known for its well-preserved medieval old town and lakeside setting on Lake Murten.
-
E.
Lambermont
Lambermont is the official residence of the Prime Minister of Belgium, located in Brussels.
- F. None of above. chosen
Statements (13)
| Predicate | Object |
|---|---|
| instanceOf |
clinical trial
ⓘ
phase III clinical trial ⓘ |
| evaluates |
efficacy of faricimab
ⓘ
faricimab NERFINISHED ⓘ safety of faricimab ⓘ |
| hasConditionCategory |
age-related macular degeneration
GENERATED
ⓘ
retinal disease GENERATED ⓘ |
| hasPhase | Phase III ⓘ |
| hasPrimaryIndication |
neovascular age-related macular degeneration
ⓘ
wet age-related macular degeneration ⓘ |
| hasTherapeuticArea | ophthalmology ⓘ |
| studies | treatment of neovascular (wet) age-related macular degeneration ⓘ |
| usesIntervention | faricimab ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Subject: LUCERNE Description of subject: LUCERNE is a large phase III clinical trial evaluating the efficacy and safety of faricimab for the treatment of neovascular (wet) age-related macular degeneration.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.